AFM and dry age related macular degeneration: These preliminary results provide further support to the hypothesis that αLβ2 or α4β1 integrin can be considered as valuable drug targets in retinal diseases and that the integrin antagonists employed in the present study could be useful to develop new therapeutic agents useful to fight dry AMD.